22nd Annual Cancer Immunotherapy Symposium of the Cancer Research Institute

New York, New York
Monday, October 06, 2014

Cancer Immunotherapy: Out of the Gate 
The Cancer Research Institute (CRI) is hosting the 22nd Annual International Cancer Immunotherapy Symposium October 6-8, 2014 at The Grand Hyatt in New York City. Attracting clinicians, laboratory scientists, postdoctoral fellows, and graduate students, the symposium will feature plenary presentations from leaders in immunology and cancer immunotherapy, a poster session, and numerous networking opportunities. This year’s symposium, entitled Cancer Immunotherapy: Out of the Gate, will harness the excitement and enthusiasm generated by recent clinical successes to explore new and emerging areas of basic, translational, and clinical research. Topics such as the use of genomic methods to catalogue cancer heterogeneity, mechanistic studies of checkpoint blockage antibodies, new views on immunosurveillance and immunoregulation, and emerging therapies that are altering the landscape of cancer treatment will be discussed. Come hear the latest developments from the scientists who are leading the charge.

Planning Committee: James P. Allison, The University of Texas MD Anderson Cancer Center; Glenn Dranoff, Dana-Farber Cancer Institute; Carl F. Nathan, Weill Cornell Medical College; Ellen Puré, University of Pennsylvania School of Veterinary Medicine; Robert D. Schreiber, Washington University School of Medicine; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center

New This Year: CIC Satellite Meeting -- Sunday, October 5
The Cancer Immunotherapy Consortium (CIC) has evolved into a "think tank' through which the cancer immunotherapy stakeholders from academia, industry, regulatory bodies, and patients, convene and tackle, on an annual basis, one topic of importance to the development of immunotherapies. The October 5 meeting entitled Development of Surrogate Endpoints for Cancer Immunotherapy Trials will consist of a full day of presentations and panel discussions addressing the key rationale, challenges, and solutions surrounding the development of surrogate endpoints for cancer immunotherapy. The output of the meeting will be a consensus-driven roadmap for the efficient regulatory approval of future immunotherapies. The meeting will be divided into two parts: The Role of Preclinical Models in Early-Stage Combinations and Surrogate Endpoints in Late-Stage Trial Development.

Organizing Committee: James Allison, The University of Texas MD Anderson Cancer Center; Dan Chen, Genentech; Tai Tseng-Chen, Bristol Myers Squibb; Chuck Drake, Johns Hopkins; Alexander Eggermont, Institut Gustave-Roussy; Keith Flaherty, Massachusetts General Hospital; Tom Gajewski, University of Chicago; Axel Hoos, GlaxoSmithKline; Patrick Hwu, The University of Texas MD Anderson Cancer Center; Ramy Ibrahim, AstraZeneca; Elizabeth Jaffee, Johns Hopkins; Michael Kalos, Eli Lilly; Hy Levitsky, Roche Glycart AG; Nils Lonberg, Bristol-Myers Squibb; Ira Mellman, Genentech; Kunle Odunsi, Roswell Park Cancer Institute; Ron Peck, Bristol-Myers Squibb; Eric Rubin, Merck; Ellen Sigal, Friends of Cancer Research; Bob Vonderheide, University of Pennsylvania; Sjoerd van der Burg, Leiden University; Jedd Wolchok, Memorial Sloan Kettering Cancer Center

Separate registration for the CIC Satellite Meeting is required. Attendance is complimentary for 2014 CRI Symposium registrants, but space is limited. After you have completed your symposium registration, click here to register for the CIC Meeting. Registration fees will apply for those not attending the symposium.

International Cancer Immunotherapy Series
Inaugurated in 1993, the Cancer Research Institute International Cancer Immunotherapy Symposium Series is designed to accelerate the understanding and development of immune system-based therapies for cancer by convening the field's leaders to share the most up-to-date data on topics of current relevance in the field. These annual meetings focus attention on progress in the two central approaches of cancer immunology -- cancer vaccines and antibody-based therapies.

Cancer Research Institute
The Cancer Research Institute was founded in 1953 to foster the science of cancer immunology. It is the world's only non-profit organization dedicated exclusively to the support and coordination of laboratory and clinical efforts that will lead to the immunological treatment, control, and prevention of cancer. As the initiator and steward of unprecedented global scientific and clinical collaboration, the Cancer Research Institute is ushering a new era of scientific progress, hastening the discovery of effective cancer vaccines and other immune-based therapies that are providing new hope to patients.

Important Dates

Friday, August 15, 2014  Poster abstract submission deadline 
  Early registration deadline
   

 

Contact Information

  • Cancer Research Institute
    (212) 688-7515

© 2015
Quick, easy and affordable online event registration and event management software for all event sizes.